Breaking Drug News: Combination GLP-1s, Treatment for Kids, and Lp(a)

What do new drug reports really mean for your treatment? Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues. KEY TAKEAWAYS Understanding the difference between efficacy estimand and treatment policy estimand. Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes. Semaglutide's effectiveness in children and its implications. NOTABLE QUOTE "Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper LINKS & RESOURCES Learn more about Diabesity Foundations: learn.diabesityinstitute.org Podcast Home: fatsciencepodcast.com Cooper Center for Metabolism: coopermetabolic.com Diabesity Institute: diabesityinstitute.org Resources from Dr. Cooper: coopermetabolic.com/resources Join Our Community: patreon.com/cw/FatSciencePodcast Submit Your Question: [email protected] or [email protected] Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care. This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.